• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    18.52 -0.35 (-1.85%)
    Official Closing Price Updated: 7:00 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,808,457
    Open 18.63
    Bid (Size) 18.37 (1)
    Ask (Size) 18.63 (1)
    Prev. Close 18.87
    Today's Range 18.37 - 18.88
    52wk Range 8.055 - 18.89
    Shares Outstanding 1,110,352,397
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
    Via Benzinga
    Organon Stock Sees Relative Strength Rating Rise To 91
    On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
    Via Investor's Business Daily

    Performance

    YTD
    +73.57%
    +73.57%
    1 Month
    +11.03%
    +11.03%
    3 Month
    +11.37%
    +11.37%
    6 Month
    +36.78%
    +36.78%
    1 Year
    +93.72%
    +93.72%

    More News

    Read More
    Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
    Via Benzinga
    Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    $100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
    Via Benzinga
    Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
    Via Investor's Business Daily
    $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    The 7 Best Under $20 Stocks to Buy in August 2024
    Via InvestorPlace
    Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
    Via PressReach
    Exposures Product Safety
    What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
    Via InvestorPlace
    Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales
    Via Benzinga
    Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise
    Via Investor's Business Daily
    Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Why Hims & Hers Heath Shares Are Surging Today
    Via Benzinga
    Teva's Migraine Treatment Found Effective For Children As Young As 6
    Via Benzinga
    Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.